BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bao P, Potter D, Eisenberg DP, Lenzner D, Zeh HJ, Lee Iii KK, Hughes SJ, Sanders MK, Young JL, Moser AJ. Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma. HPB (Oxford). 2009;11:606-611. [PMID: 20495714 DOI: 10.1111/j.1477-2574.2009.00110.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Riall TS, Brown KM. Individualizing care for locoregional pancreatic cancer? J Surg Res 2013;179:41-4. [PMID: 22221606 DOI: 10.1016/j.jss.2011.10.041] [Reference Citation Analysis]
2 Khreiss M, Zeh HJ, Boone BA, Zureikat AH. Robotic-Assisted Pancreatoduodenectomy. Curr Surg Rep 2013;1:98-105. [DOI: 10.1007/s40137-013-0017-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Zeh HJ, Bahary N, Boone BA, Singhi AD, Miller-Ocuin JL, Normolle DP, Zureikat AH, Hogg ME, Bartlett DL, Lee KK, Tsung A, Marsh JW, Murthy P, Tang D, Seiser N, Amaravadi RK, Espina V, Liotta L, Lotze MT. A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Clin Cancer Res 2020;26:3126-34. [PMID: 32156749 DOI: 10.1158/1078-0432.CCR-19-4042] [Cited by in Crossref: 40] [Cited by in F6Publishing: 18] [Article Influence: 20.0] [Reference Citation Analysis]
4 Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, Mohile SG, Mumber M, Schulick R, Shapiro M, Urba S, Zeh HJ, Katz MH. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2541-2556. [PMID: 27247221 DOI: 10.1200/jco.2016.67.5553] [Cited by in Crossref: 195] [Cited by in F6Publishing: 80] [Article Influence: 32.5] [Reference Citation Analysis]
5 Boone BA, Bahary N, Zureikat AH, Moser AJ, Normolle DP, Wu WC, Singhi AD, Bao P, Bartlett DL, Liotta LA, Espina V, Loughran P, Lotze MT, Zeh HJ. Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Ann Surg Oncol. 2015;22:4402-4410. [PMID: 25905586 DOI: 10.1245/s10434-015-4566-4] [Cited by in Crossref: 108] [Cited by in F6Publishing: 104] [Article Influence: 15.4] [Reference Citation Analysis]
6 Boone BA, Steve J, Zenati MS, Hogg ME, Singhi AD, Bartlett DL, Zureikat AH, Bahary N, Zeh HJ 3rd. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol. 2014;21:4351-4358. [PMID: 25092157 DOI: 10.1245/s10434-014-3842-z] [Cited by in Crossref: 104] [Cited by in F6Publishing: 90] [Article Influence: 13.0] [Reference Citation Analysis]
7 Zeh HJ, Zureikat AH, Secrest A, Dauoudi M, Bartlett D, Moser AJ. Outcomes after robot-assisted pancreaticoduodenectomy for periampullary lesions. Ann Surg Oncol. 2012;19:864-870. [PMID: 21947670 DOI: 10.1245/s10434-011-2045-0] [Cited by in Crossref: 102] [Cited by in F6Publishing: 90] [Article Influence: 9.3] [Reference Citation Analysis]
8 Tummala P, Howard T, Agarwal B. Dramatic Survival Benefit Related to R0 Resection of Pancreatic Adenocarcinoma in Patients With Tumor ≤25 mm in Size and ≤1 Involved Lymph Nodes. Clin Transl Gastroenterol 2013;4:e33. [PMID: 23515131 DOI: 10.1038/ctg.2013.4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
9 Zureikat AH, Breaux JA, Steel JL, Hughes SJ. Can laparoscopic pancreaticoduodenectomy be safely implemented? J Gastrointest Surg. 2011;15:1151-1157. [PMID: 21538192 DOI: 10.1007/s11605-011-1530-x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 9.4] [Reference Citation Analysis]
10 Boyd CA, Branch DW, Sheffield KM, Han Y, Kuo YF, Goodwin JS, Riall TS. Hospital and medical care days in pancreatic cancer. Ann Surg Oncol 2012;19:2435-42. [PMID: 22451235 DOI: 10.1245/s10434-012-2326-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
11 Zeh HJ 3rd, Bartlett DL, Moser AJ. Robotic-assisted major pancreatic resection. Adv Surg 2011;45:323-40. [PMID: 21954697 DOI: 10.1016/j.yasu.2011.04.001] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
12 Paniccia A, Gleisner AL, Zenati MS, Al Abbas AI, Jung JP, Bahary N, Lee KKW, Bartlett D, Hogg ME, Zeh HJ, Zureikat AH. Predictors of Disease Progression or Performance Status Decline in Patients Undergoing Neoadjuvant Therapy for Localized Pancreatic Head Adenocarcinoma. Ann Surg Oncol 2020;27:2961-71. [DOI: 10.1245/s10434-020-08257-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
13 De Lellis L, Veschi S, Tinari N, Mokini Z, Carradori S, Brocco D, Florio R, Grassadonia A, Cama A. Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates. Cancers (Basel) 2021;13:3946. [PMID: 34439102 DOI: 10.3390/cancers13163946] [Reference Citation Analysis]
14 Rahman SH, Urquhart R, Molinari M. Neoadjuvant therapy for resectable pancreatic cancer. World J Gastrointest Oncol 2017; 9(12): 457-465 [PMID: 29290916 DOI: 10.4251/wjgo.v9.i12.457] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
15 Versteijne E, Vogel JA, Besselink MG, Busch ORC, Wilmink JW, Daams JG, van Eijck CHJ, Groot Koerkamp B, Rasch CRN, van Tienhoven G;  Dutch Pancreatic Cancer Group. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105:946-958. [PMID: 29708592 DOI: 10.1002/bjs.10870] [Cited by in Crossref: 168] [Cited by in F6Publishing: 154] [Article Influence: 42.0] [Reference Citation Analysis]
16 AlMasri SS, Zenati MS, Desilva A, Nassour I, Boone BA, Singhi AD, Bartlett DL, Liotta LA, Espina V, Loughran P, Lotze MT, Paniccia A, Zeh HJ 3rd, Zureikat AH, Bahary N. Encouraging long-term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high-risk patients with resectable pancreatic carcinoma. Cancer Med 2021;10:7233-41. [PMID: 34559451 DOI: 10.1002/cam4.4211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Bao PQ, Ramanathan RK, Krasinkas A, Bahary N, Lembersky BC, Bartlett DL, Hughes SJ, Lee KK, Moser AJ, Zeh HJ. Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol. 2011;18:1122-1129. [PMID: 21104328 DOI: 10.1245/s10434-010-1401-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]